Rapid Therapeutic Science Lab inc
Rapid Therapeutic Science Laboratories, Inc. focuses on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013… Read more
Rapid Therapeutic Science Lab inc (RTSL) - Net Assets
Latest net assets as of December 2024: $-3.08 Million USD
Based on the latest financial reports, Rapid Therapeutic Science Lab inc (RTSL) has net assets worth $-3.08 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($967.76K) and total liabilities ($4.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.08 Million |
| % of Total Assets | -318.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -6796.37% |
| Growth Volatility | 28.83 |
Rapid Therapeutic Science Lab inc - Net Assets Trend (2012–2024)
This chart illustrates how Rapid Therapeutic Science Lab inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Rapid Therapeutic Science Lab inc (2012–2024)
The table below shows the annual net assets of Rapid Therapeutic Science Lab inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-3.08 Million | +1.80% |
| 2022-12-31 | $-3.14 Million | -127.35% |
| 2021-12-31 | $-1.38 Million | -1.27% |
| 2019-12-31 | $-1.36 Million | +52.33% |
| 2018-12-31 | $-2.86 Million | 0.00% |
| 2018-03-31 | $-2.86 Million | -12397.93% |
| 2017-12-31 | $-22.91K | -1676.96% |
| 2016-03-31 | $-1.29K | 0.00% |
| 2015-12-31 | $-1.29K | -102.80% |
| 2014-12-31 | $46.07K | -45.15% |
| 2012-12-31 | $83.98K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rapid Therapeutic Science Lab inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1045938500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.99K | % |
| Other Components | $7.37 Million | % |
| Total Equity | $-3.08 Million | 100.00% |
Rapid Therapeutic Science Lab inc Competitors by Market Cap
The table below lists competitors of Rapid Therapeutic Science Lab inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daesung Energy Co. Ltd.
KQ:117580
|
$65.15K |
|
YOC (YOC.SG)
STU:YOC
|
$65.39K |
|
Valamar Riviera d.d.
ZSE:RIVP
|
$65.40K |
|
AVINO SILVER & GOLD
MU:GV6
|
$65.40K |
|
Atos SE
PINK:AEXAF
|
$64.82K |
|
ITUB3F
SA:ITUB3F
|
$64.82K |
|
Mmcité a.s.
PR:MMCTE
|
$64.78K |
|
Soiltech ASA
OL:STECH
|
$64.73K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rapid Therapeutic Science Lab inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2024, total equity changed from -3,141,483 to -3,084,885, a change of 56,598.
- Net loss of 183,296 reduced equity.
- Other factors increased equity by 239,894.
Equity Change Factors (2022 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-183.30K | -5.94% |
| Other Changes | $239.89K | +7.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Rapid Therapeutic Science Lab inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.21 | $0.01 | x |
| 2015-12-31 | $-0.01 | $0.01 | x |
| 2016-03-31 | $-0.01 | $0.01 | x |
| 2017-12-31 | $-0.21 | $0.01 | x |
| 2018-03-31 | $-29.02 | $0.01 | x |
| 2018-12-31 | $-29.02 | $0.01 | x |
| 2019-12-31 | $-28.33 | $0.01 | x |
| 2021-12-31 | $-0.18 | $0.01 | x |
| 2022-12-31 | $-0.41 | $0.01 | x |
| 2024-12-31 | $-0.16 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rapid Therapeutic Science Lab inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-8.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -82.30% | 0.00% | 0.00x | 1.00x | $-21.26K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.17K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.89K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.33K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.27 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.27 Million |
| 2019 | 0.00% | -3817.06% | 0.02x | 0.00x | $-212.39K |
| 2021 | 0.00% | -786015.73% | 0.00x | 0.00x | $-4.06 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.38 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $125.19K |
Industry Comparison
This section compares Rapid Therapeutic Science Lab inc's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rapid Therapeutic Science Lab inc (RTSL) | $-3.08 Million | -82.30% | N/A | $65.11K |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |